Cargando…
Trial watch: TLR3 agonists in cancer therapy
Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion of pro-inflammatory cytokines including type...
Autores principales: | Le Naour, Julie, Galluzzi, Lorenzo, Zitvogel, Laurence, Kroemer, Guido, Vacchelli, Erika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466857/ https://www.ncbi.nlm.nih.gov/pubmed/32934877 http://dx.doi.org/10.1080/2162402X.2020.1771143 |
Ejemplares similares
-
Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020) -
Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)